This is a duplicate of my Dry Eye Digest blogspot blog - to see the full archives back to 2005, please click on that link.
This is 'early-stage' stuff with test tubes and bunny eyes but it's interesting stuff from an excellent research group in France looking at what makes or mars the delivery of cyclosporine for dry eye, concluding that cationic emulsion is better.
Ocular safety of cationic emulsion of cyclosporine in an invitro corneal wound-healing model and an acute in vivo rabbit model.
Topical preparations of cyclosporine (CsA) are common therapeutics for the treatment
A novel cyclosporin A aqueous formulation for dry eye treatment: in vitro and in vivo evaluation.
Purpose: The aim of the present study was the in vitro and in vivo evaluation of a novel aqueous formulation based on polymeric micelles for the topical delivery of cyclosporin A (CsA) for dry eye treatment.
Methods: In vitro experiments were carried out on primary rabbit corneal cells, which were characterized by immunocytochemistry using fluorescein-labelled lectin I/isolectin
Extended cyclosporine delivery by silicone-hydrogel contact lenses.
Cyclosporine A (CyA) is effective in treating chronic dry eyes and contact lens mediated dry eyes. CyA is delivered through eye drops of an oil-in-water emulsion, which has a small residence time in the eyes, leading to low bioavailability. Here we explore delivery of CyA from contact lenses to provide controlled and extended drug delivery with an increased bioavailability due to enhanced ocular residence time. Loading and
Development and characterization of cyclosporine a loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
Dry eye syndrome is a common disorder of the tear film caused by decreased tear production or increased evaporation. The objective of this study was to evaluate the potential effectiveness of Cyclosporine A (CsA) nanoparticles (NPs) for the treatment of inflammation of the eye surface. Topical CsA is currently the only and safe pharmacologic